Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Pertuzumab: development beyond breast cancer.

Barthélémy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE.

Anticancer Res. 2014 Apr;34(4):1483-91. Review.

PMID:
24692675
2.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
3.

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

O'Sullivan CC, Swain SM.

Expert Opin Biol Ther. 2013 May;13(5):779-90. doi: 10.1517/14712598.2013.783007. Epub 2013 Mar 27. Review.

PMID:
23530718
4.

[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].

Sabatier R, Gonçalves A.

Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940. French.

PMID:
25091659
5.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722
6.

Pertuzumab: optimizing HER2 blockade.

Metzger-Filho O, Winer EP, Krop I.

Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Review.

7.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
8.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
9.

Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.

McCormack PL.

Drugs. 2013 Sep;73(13):1491-502. doi: 10.1007/s40265-013-0109-0. Review.

PMID:
23982598
10.

Pertuzumab in the treatment of HER2+ breast cancer.

Jhaveri K, Esteva FJ.

J Natl Compr Canc Netw. 2014 Apr;12(4):591-8. Review.

PMID:
24717573
11.

Pertuzumab in breast cancer: a systematic review.

Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, Dimopoulos MA, Psaltopoulou T.

Clin Breast Cancer. 2013 Oct;13(5):315-24. doi: 10.1016/j.clbc.2013.05.002. Epub 2013 Jun 27. Review.

PMID:
23810292
12.

Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.

Keating GM.

Drugs. 2012 Feb 12;72(3):353-60. doi: 10.2165/11209000-000000000-00000. Review.

PMID:
22316351
13.

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.

Kristjansdottir K, Dizon D.

Expert Opin Biol Ther. 2010 Feb;10(2):243-50. doi: 10.1517/14712590903514090. Review.

PMID:
20001562
14.
15.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
16.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

17.

Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.

Malenfant SJ, Eckmann KR, Barnett CM.

Pharmacotherapy. 2014 Jan;34(1):60-71. doi: 10.1002/phar.1338. Epub 2013 Aug 5. Review.

PMID:
23918291
18.

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

Baselga J, Swain SM.

Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.

PMID:
21147694
19.

Pertuzumab for the treatment of metastatic breast cancer.

Langdon SP, Cameron DA.

Expert Rev Anticancer Ther. 2013 Aug;13(8):907-18. doi: 10.1586/14737140.2013.814419. Review.

PMID:
23984893
20.

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

Smith MB, Reardon J, Olson EM.

Drugs Today (Barc). 2012 Nov;48(11):713-22. doi: 10.1358/dot.2012.48.11.1885879. Review.

Items per page

Supplemental Content

Write to the Help Desk